MCID: LYM002
MIFTS: 35

Lymphoplasmacyte-Rich Meningioma

Categories: Cancer diseases, Immune diseases, Neuronal diseases

Aliases & Classifications for Lymphoplasmacyte-Rich Meningioma

MalaCards integrated aliases for Lymphoplasmacyte-Rich Meningioma:

Name: Lymphoplasmacyte-Rich Meningioma 12 15 17 70
Lymphoplasmocyte-Rich Meningioma 12
Meningioma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4591
NCIt 50 C4720
SNOMED-CT 67 19453003
UMLS 70 C0025286 C0431119

Summaries for Lymphoplasmacyte-Rich Meningioma

MalaCards based summary : Lymphoplasmacyte-Rich Meningioma, also known as lymphoplasmocyte-rich meningioma, is related to meningioma, familial and intracranial meningioma. An important gene associated with Lymphoplasmacyte-Rich Meningioma is MIB1 (MIB E3 Ubiquitin Protein Ligase 1), and among its related pathways/superpathways are Cell adhesion molecules and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include pituitary, spinal cord and brain.

Related Diseases for Lymphoplasmacyte-Rich Meningioma

Diseases related to Lymphoplasmacyte-Rich Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 18)
# Related Disease Score Top Affiliating Genes
1 meningioma, familial 10.9
2 intracranial meningioma 10.9
3 secretory meningioma 10.9
4 rapidly involuting congenital hemangioma 10.9
5 rosai-dorfman disease 10.4
6 igg4-related disease 10.4
7 brain edema 10.4
8 idiopathic hypertrophic pachymeningitis 10.4
9 igg4-related pachymeningitis 10.4
10 brain meningioma 10.1
11 fibrous dysplasia 10.1
12 optic nerve disease 10.1
13 hyperostosis 10.1
14 histiocytosis 10.1
15 jugular foramen meningioma 10.1
16 angiomatous meningioma 10.1
17 dysphagia 10.1
18 posttransplant acute limbic encephalitis 10.1

Graphical network of the top 20 diseases related to Lymphoplasmacyte-Rich Meningioma:



Diseases related to Lymphoplasmacyte-Rich Meningioma

Symptoms & Phenotypes for Lymphoplasmacyte-Rich Meningioma

Drugs & Therapeutics for Lymphoplasmacyte-Rich Meningioma

Drugs for Lymphoplasmacyte-Rich Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Prilocaine Approved Phase 4 721-50-6 4906
6
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
7 Fibrin Tissue Adhesive Phase 4
8 Neurotransmitter Agents Phase 4
9 Antifibrinolytic Agents Phase 4
10 Coagulants Phase 4
11 Hemostatics Phase 4
12 Pharmaceutical Solutions Phase 4
13 Anesthetics Phase 4
14 Vasoconstrictor Agents Phase 4
15 Anesthetics, Local Phase 4
16 Respiratory System Agents Phase 4
17 Adrenergic alpha-Agonists Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Adrenergic beta-Agonists Phase 4
20 Epinephryl borate Phase 4
21 Adrenergic Agonists Phase 4
22 Adrenergic Agents Phase 4
23 Mydriatics Phase 4
24 Sympathomimetics Phase 4
25 Bronchodilator Agents Phase 4
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
27
Cisatracurium Approved Phase 3 96946-41-7 62887
28
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
29
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
30
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
31
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
32
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
33
Aminolevulinic acid Approved Phase 3 106-60-5 137
34 Antihypertensive Agents Phase 3
35 Contraceptives, Postcoital Phase 3
36 Contraceptives, Oral Phase 3
37 Contraceptive Agents Phase 3
38 Progestins Phase 3
39 Photosensitizing Agents Phase 3
40 Dermatologic Agents Phase 3
41
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
42
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
43
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
44
Hydroxyurea Approved Phase 2 127-07-1 3657
45
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
46
Verapamil Approved Phase 2 52-53-9 2520
47
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
48
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
49
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
50
Mesna Approved, Investigational Phase 2 3375-50-6 598

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction Not yet recruiting NCT04756050 Phase 4 Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg
6 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
7 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
8 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
9 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
10 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
11 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
12 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
13 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
14 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Unknown status NCT01849484 Phase 2
15 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
16 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
17 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
18 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
19 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
20 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
21 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
22 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
23 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
24 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
25 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
26 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Completed NCT00006119 Phase 2 hydroxyurea
27 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
28 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
29 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
30 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
31 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
32 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
33 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
34 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
35 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
36 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
37 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib
38 A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
39 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
40 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
41 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
42 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
43 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
44 A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma Recruiting NCT04659811 Phase 2 Pembrolizumab
45 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
46 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
47 Phase II, Dosimetry Guided, Peptide Receptor Radiotherapy (PRRT) Using 90Y-DOTA tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Positive Tumors Recruiting NCT03273712 Phase 2 Amino Acids
48 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
49 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Active, not recruiting NCT00895622 Phase 2
50 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Active, not recruiting NCT00626730 Phase 2

Search NIH Clinical Center for Lymphoplasmacyte-Rich Meningioma

Genetic Tests for Lymphoplasmacyte-Rich Meningioma

Anatomical Context for Lymphoplasmacyte-Rich Meningioma

MalaCards organs/tissues related to Lymphoplasmacyte-Rich Meningioma:

40
Pituitary, Spinal Cord, Brain, Pineal, Endothelial, Prostate, Myeloid

Publications for Lymphoplasmacyte-Rich Meningioma

Articles related to Lymphoplasmacyte-Rich Meningioma:

(show top 50) (show all 15062)
# Title Authors PMID Year
1
Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells. 61
33622177 2021
2
Case report 68Ga-DOTATATE of optic nerve sheath meningioma. 61
33748535 2021
3
KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. 61
33652084 2021
4
Proton therapy: A therapeutic opportunity for aggressive pediatric meningioma. 61
33682333 2021
5
Value of KI-67/MIB-1 labeling index and simpson grading system to predict the recurrence of who grade I intracranial meningiomas compared to who grade II. 61
33775343 2021
6
WHO classification of meningiomas-A single institutional experience. 61
33144180 2021
7
Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience. 61
33449307 2021
8
Cognitive reserve protects language functions in patients with brain tumours. 61
33524456 2021
9
A cohort study on adult hematological malignancies and brain tumors in relation to magnetic fields from indoor transformer stations. 61
33601135 2021
10
Demographic and socioeconomic disparities of benign and malignant spinal meningiomas in the United States. 61
33068594 2021
11
Novel histopathological classification of meningiomas based on dural invasion. 61
32546547 2021
12
Intracranial long-term complications of radiation therapy: an image-based review. 61
33392738 2021
13
The Stanford stereotactic radiosurgery experience on 7000 patients over 2 decades (1999-2018): looking far beyond the scalpel. 61
33799297 2021
14
Postpartum Recovery From Meningioma-Related Oculomotor Palsy. 61
33706360 2021
15
Late malignant transformation of anaplastic meningioma 18 years after primary surgery: A case report. 61
33775317 2021
16
Clinical Outcome and Recurrence After Meningioma Surgery: An Experience from a Developing Country, Nepal. 61
33359878 2021
17
In-Hospital Complications After Surgery in Elderly Patients with Asymptomatic or Minor Symptom Meningioma: A Nationwide Registry Study. 61
33444840 2021
18
Cavernous Sinus Meningioma Resection Through Orbitozygomatic Craniotomy. 61
33515796 2021
19
The histopathological diagnosis of atypical meningioma: glass slide versus whole slide imaging for grading assessment. 61
33305338 2021
20
Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients. 61
33528717 2021
21
Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy. 61
33190809 2021
22
Intraparenchymal supratentorial papillary meningioma: a case report. 61
29564936 2021
23
Orbital decompressive effect of endoscopic transorbital surgery for sphenoorbital meningioma. 61
33226438 2021
24
[Retracted] α3β1 integrin promotes radiation-induced migration of meningioma cells. 61
33655324 2021
25
Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. 61
32859705 2021
26
Effect of Surgeon Experience on Surgical Outcome of 80-Year-Old or Older Intracranial Meningioma Patients. 61
33422717 2021
27
A rare case of parasagittal meningioma causing isolated foot drop: case report and review of the literature. 61
31786742 2021
28
Trends in the Management Paradigms of Intracranial Meningioma. 61
33777636 2021
29
Case report of primary dural lymphoma mimicking a cerebellar meningioma and brief review of literature. 61
31301042 2021
30
[Spinal tumors]. 61
33570679 2021
31
Clinical and Neuroimaging Features of Magnetic Resonance-Guided Stereotactic Laser Ablation for Newly Diagnosed and Recurrent Pediatric Brain Tumors: A Single Institutional Series. 61
33722713 2021
32
Machine learning may predict individual hand motor activation from resting-state fMRI in patients with brain tumors in perirolandic cortex. 61
33758954 2021
33
Chlorhexidine: An important cause of perioperative anaphylaxis. 61
33752780 2021
34
Raman Spectral Signatures of Serum-Derived Extracellular Vesicle-Enriched Isolates May Support the Diagnosis of CNS Tumors. 61
33808766 2021
35
Approach to patient with unilateral optic disc edema and normal visual function. 61
33799215 2021
36
Supratentorial primary paraganglioma with good long-term outcome following radical excision. 61
33754919 2021
37
The Zap-X Radiosurgical System in the Treatment of Intracranial Tumors: A Technical Case Report. 61
33442727 2021
38
Cranial MRI abnormalities and long-term follow-up of the lesions in 770 girls with Central Precocious Puberty. 61
33765130 2021
39
Sterile Gelatin Film Reduces Cortical Injury Associated With Brain Tumor Re-Resection. 61
33373437 2021
40
[Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study]. 61
33677887 2021
41
Clinical outcome after microsurgical resection of intraventricular trigone meningiomas: a single-centre analysis of 20 years and literature overview. 61
32772161 2021
42
Deep learning approaches for automated classification and segmentation of head and neck cancers and brain tumors in magnetic resonance images: a meta-analysis study. 61
33666859 2021
43
Gaze-evoked amaurosis from idiopathic orbital inflammation. 61
33781156 2021
44
The expanded endoscopic endonasal approach for treatment of tuberculum sellae meningiomas in a series of 40 consecutive cases. 61
33654211 2021
45
The Prognostic Value of Methylation Signatures and NF2 Mutations in Atypical Meningiomas. 61
33809258 2021
46
The endoscope-assisted supraorbital "keyhole" approach for anterior skull base meningiomas: an updated meta-analysis. 61
32889640 2021
47
Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas. 61
33716047 2021
48
The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma. 61
33508276 2021
49
Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. 61
33772057 2021
50
The impact of authors' medical specialty on publication patterns and published results of adjuvant radiotherapy for WHO grade 2 meningiomas-a systematic review. 61
33779837 2021

Variations for Lymphoplasmacyte-Rich Meningioma

Expression for Lymphoplasmacyte-Rich Meningioma

Search GEO for disease gene expression data for Lymphoplasmacyte-Rich Meningioma.

Pathways for Lymphoplasmacyte-Rich Meningioma

Pathways related to Lymphoplasmacyte-Rich Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.13 SDC1 CLDN6
2 10.69 SDC1 CD163

GO Terms for Lymphoplasmacyte-Rich Meningioma

Biological processes related to Lymphoplasmacyte-Rich Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytosis GO:0006897 8.62 MIB1 CD163

Sources for Lymphoplasmacyte-Rich Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....